RTP Mobile Logo
Beyond the Guidelines: Investigator Perspectives on Current Clinical Issues and Ongoing Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma
Released August 2018

Proceedings from a CME symposium held at the 2018 ASCO Annual Meeting. Featuring perspectives from Drs Stephen Maxted Ansell, Matthew S Davids, Rafael Fonseca, Paul G Richardson, Laurie H Sehn and Anas Younes. (Video Program)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

    Hematologic cancers include the lymphomas, the leukemias, multiple myeloma (MM) and other related disorders stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 174,250 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2018, and 56,100 individuals will die from these diseases. Importantly, nearly 70 drug products are currently labeled for use in the management of hematologic cancers with more than 120 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors. This is particularly true, however, within the realm of Hodgkin and non-Hodgkin lymphoma (including chronic lymphocytic leukemia [CLL]) and MM, where the past several years have seen a staggering number of important clinical and research advances.

    Several consensus- and evidence-based treatment guidelines are available and aim to assist clinicians with making management decisions in this dynamic clinical and research environment. However, in situations where multiple acceptable therapeutic options exist, such guidelines may not be particularly helpful at the time of decision-making. By exploring the perspectives of leading investigators regarding a number of clinical scenarios and reviewing key data sets, this activity will assist medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals in the development of evidence-based strategies for the treatment of hematologic cancers.


    • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed and relapsed/refractory (R/R) CLL, considering clinical presentation, biomarker profile and psychosocial status.
    • Consider existing and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and R/R diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma.
    • Incorporate new therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
    • Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
    • Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with R/R MM.
    • Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational immunotherapeutic approaches (eg, immune checkpoint inhibitors, chimeric antigen receptor-directed T-cell therapy) for the treatment of HL, non-Hodgkin lymphoma (NHL), CLL and MM to determine the current and/or potential utility of each in clinical practice.
    • Design and implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies in the management of HL, NHL, CLL and MM to support quality of life and continuation of treatment.
    • Assess the ongoing clinical trials evaluating other novel investigational approaches for HL, NHL, CLL and MM, and obtain consent from appropriate patients for study participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOHem18/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Stephen Maxted Ansell, MD, PhD
    Professor of Medicine
    Division of Hematology
    Mayo Clinic
    Rochester, Minnesota

    Clinical Trials: Affimed, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc, Takeda Oncology, Trillium Therapeutics Inc.

    Matthew S Davids, MD, MMSc
    Associate Director, Center for Chronic Lymphocytic Leukemia
    Assistant Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Incyte Corporation, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Janssen Biotech Inc, MEI Pharma Inc, Merck, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Verastem Inc; Contracted Research: Bristol-Myers Squibb Company, Genentech, MEI Pharma Inc, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc.

    Rafael Fonseca, MD
    Getz Family Professor of Cancer
    Chair, Department of Internal Medicine
    Mayo Clinic Arizona
    Scottsdale, Arizona

    Advisory Committee: Amgen Inc, Janssen Biotech Inc; Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Oncology.

    Paul G Richardson, MD
    Clinical Program Leader
    Director of Clinical Research
    Jerome Lipper Multiple Myeloma Center
    Department of Medical Oncology
    Dana-Farber Cancer Institute
    RJ Corman Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Novartis, Takeda Oncology.

    Laurie H Sehn, MD, MPH
    Centre for Lymphoid Cancer
    BC Cancer Agency and University of British Columbia
    Vancouver, British Columbia, Canada

    Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Janssen Biotech Inc, Lundbeck, Roche Laboratories Inc, Seattle Genetics, Takeda Oncology.

    Anas Younes, MD
    Chief, Lymphoma Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Janssen Biotech Inc, Merck, Novartis; Contracted Research: Bristol-Myers Squibb Company, Novartis.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, Gilead Sciences Inc and Seattle Genetics.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: August 2018
    Expiration date: August 2019

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):